Clinical Trial Updates - ALPACAR-360 Phase 2 study of Zerlasiran delivered positive results in high Lp(a)[9, 10] - SANRECO Phase 1 study of Divesiran delivered positive results in PV and was granted orphan drug designation for PV in EU[9, 10] - SANRECO Phase 2 study of Divesiran dosed first PV patient, with full enrollment anticipated by year-end 2025[10, 12, 48] - SLN548 (complement factor B) Phase 1 study start anticipated in 2H 2025[12, 48] Divesiran in Polycythemia Vera (PV) - Divesiran is a first-in-class siRNA for PV with FDA Fast Track and Orphan Drug Designations[26, 27] - Phase 1 study showed Divesiran reduced phlebotomy frequency in PV patients who had 79 phlebotomies prior to dosing, but only 5 in the treatment period and 2 in follow-up[29, 31] - Divesiran decreased hematocrit in all cohorts in Phase 1 study[32, 34] - Divesiran treatment produced sustained increases in Hepcidin[36, 38] - Divesiran demonstrated a favorable safety and tolerability profile, with 84% of treatment emergent adverse events (TEAEs) being grade 1[40, 41] Financial Performance and Guidance - Revenue for FY 2024 was $43258 thousand, compared to $31634 thousand in FY 2023[16] - Net loss for FY 2024 was $45309 thousand, compared to $54228 thousand in FY 2023[16] - Cash position at the end of December 2024 was $147334 thousand, including $121300 thousand in cash and cash equivalents and $26000 thousand in short-term investments[16, 17] - Projected cash runway extended into 2027[18]